Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy.
Vavro
C L
CL
Department of Virology, Glaxo Wellcome, Inc., Research Triangle Park, North Carolina 27709, USA.
Zimmermann
A M
AM
McClernon
D R
DR
Kehne
S L
SL
Martel
L A
LA
Valentine
M E
ME
McKinney
R E
RE
D019380:Anti-HIV Agents / Q000627:therapeutic use; D002648:Child; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000145:classification / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D016131:Lymphocyte Subsets / Q000276:immunology; D019888:Nelfinavir / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D016879:Salvage Therapy; D013997:Time Factors; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase; D019888:Nelfinavir